Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy (AOITC)

17 de setembro de 2026 atualizado por: AO Innovation Translation Center

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy: A Multi-center Retrospective Cohort Study

Osteoradionecrosis (ORN) of the jaw is a serious complication that can occur after radiation therapy for head and neck cancers, including oral cavity cancer (OCC). ORN happens when jawbone tissue dies and fails to heal, often triggered by dental issues like tooth extractions or poorly fitting dentures. Symptoms can include exposed bone, pain, difficulty opening the mouth, trouble swallowing, and even jaw fractures-leading to major physical and emotional challenges.

The likelihood of ORN varies widely, from less than 1% to over 50% in head and neck cancer patients. For OCC specifically, studies report rates from 4% up to 25%. Treatment depends on how much bone is affected and can range from medication to major surgery.

Risk factors include radiation dose, tumor location, oral health, dental extractions, lifestyle habits (like alcohol use), and other health conditions. Poor oral hygiene, high radiation doses, and alcohol use are among the most common risks. However, current data on OCC patients is limited and often not broadly applicable.

This study will retrospectively examine what increases the risk of ORN in OCC patients who received radiation therapy before or after surgery. Using data from multiple international centers, it aims to identify patterns and provide globally relevant insights. The results will help guide prevention strategies and create evidence-based guidelines to reduce ORN and improve long-term outcomes for these patients.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Tipo de estudo

Observacional

Inscrição (Estimado)

1000

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients will be selected from the primary care center where the patients received their initial treatment and followed up for at least 24months

Descrição

Inclusion Criteria:

  • Adults (≥18 years) diagnosed with OCC and treated with radiotherapy with curative intent (preoperative or/and postoperative, not palliative; definitive RT)
  • Patients who completed the full prescribed radiotherapy course; patients remain eligible if radiotherapy was discontinued due to suspected and subsequently confirmed ORN
  • Available, complete medical records including RT details, oral status, comorbidities, dental procedure details (as applicable), and lifestyle factors (as applicable)
  • Documented informed consent from the treated patient, where applicable, permitting the use of their medical records for research purposes, in accordance with the requirements of the Institutional Review Board (IRB) or Ethics Committee (EC).
  • Availability of at least 24 months of follow-up data after completion of radiotherapy, or follow-up until the occurrence of ORN, death, or loss to follow-up, whichever occurs first.
  • Completion of the radiotherapy course on or before 31 December 2024.

Exclusion Criteria:

  • Patients with non-oral cavity primary cancers (eg, oropharynx, larynx)
  • Patients treated only with surgery or conservatively, without any form of RT
  • Incomplete or missing medical records
  • Record of use of antiresorptive (eg, bisphosphonate, denosumab) and antiangiogenic drugs
  • Patients with jaw necrosis attributable to non-radiation-related causes, such as medication-related osteonecrosis of the jaw (MRONJ), trauma, or odontogenic infections
  • Patients with known metastatic bone disease in the jaw
  • Patients who discontinued radiotherapy for reasons unrelated to ORN suspicion or confirmation (eg, death, dropout, treatment intolerance, or other non-ORN related causes)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: RETROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Cases (ORN group)

Developed clinically and radiographically or histologically confirmed osteoradionecrosis (ORN) of the jaw following radiotherapy.

Control (non-ORN group)

No clinical, radiological, or histological diagnosis of ORN during the follow-up period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Development of osteoradionecrosis (ORN) of the jaw
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

The primary outcome is the development occurrence (yes/no) of ORN after completion of pre- and/or postoperative RT. The objective is to identify and evaluate patient-, tumor-, treatment-, and region-related risk factors associated with the development of ORN across multiple geographic regions.

Scoring Scale:

The primary endpoint will be treated as a binary variable:

0 = No ORN

1 = Development of ORN Time to ORN onset (interval between completion of RT and clinical diagnosis of ORN) will also be recorded for time-to-event analyses.

After completion of pre-and/or postoperative radiotherapy up to 24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of ORN Across Geographic Regions
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence rates across geographical regions, namely between the Eastern and Western world, and High-Income Countries versus Low and Middle-Income Countries.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Severity of ORN by Tumor Characteristic
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate the variability in the severity of osteoradionecrosis (ORN) based on primary tumor site (eg, tongue, floor of mouth, oral tongue, buccal mucosa, gingiva), histological tumor type (eg, adenoid cystic carcinoma, squamous cell carcinoma), and tumor characteristics including size, clinical stage (T1-T4), overall stage (III-IVA), and nodal status (N0, N1-2B, N2C, N3

After completion of pre-and/or postoperative radiotherapy up to 24 months
Association between radiotherapy dose and ORN severity
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To investigate the association between radiotherapy dose parameters (total dose and duration) and the severity grade of ORN among patients who develop ORN. Is there a correlation between increased radiation dose and duration and the severity of the condition?

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence and severity comparison of preop vs. postop RT
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence and severity of ORN in patients undergoing preoperative versus postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence comparison across RT modalities
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence ORN across different radiation modalities, including intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and conventional three-dimensional conformal radiotherapy (3D-CRT)

After completion of pre-and/or postoperative radiotherapy up to 24 months
To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Complication evaluation with pre- or postop RT
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate potential complications associated with preoperative and postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN

After completion of pre-and/or postoperative radiotherapy up to 24 months
To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT
Prazo: After completion of pre-and/or postoperative radiotherapy up to 24 months

To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT

After completion of pre-and/or postoperative radiotherapy up to 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Khalid Abdel-Galil, MD, Hamad Medical Corporation PO Box 3050 Doha, Qatar

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de março de 2027

Conclusão Primária (Estimado)

15 de junho de 2029

Conclusão do estudo (Estimado)

15 de julho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

27 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de setembro de 2026

Primeira postagem (Real)

23 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ORN of the Jaw

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .